Good science does not automatically become good decisions.
TARGET SELECTION & VALIDATION
01
Which targets should we advance?
02
What's the human evidence for this target?
Define the causal human biology that supports this target as a cause of the disease.
03
How should we modulate this target?
Inhibit, activate, or degrade: human evidence for direction
04
Which validated target is best?
LOFTierTM: Using apples-to-apples comparisons we assess which target will yield the maximum effect upon disease
05
Are there additive effects when influencing multible targets?
SynergixTM picks a combination of targets that will work beyond a standard of care.
SAFETY & RISK
06
What will we observe in early clinical trials?
Predicting early safety signals from target biology
07
What safety monitoring plan do we need?
08
What on-target side effects should we expect?
Safety profiling via genetic phenome-wide associations
BIOMARKERS & TRIAL DESIGN
09
Which biomarkers should we track?
Pharmacodynamic biomarkers to assess target engagement. Causal biomarkers to understand how the target influences the disease.
10
Which patients are most likely to benefit?
Genetic stratification for enrollment enrichment
STRATEGY & PORTFOLIO
11
Does this target affect disease progression?
Trajecta™: a target that prevents onset may have no effect in patients who already have the disease. Find out if your targets influences disease susceptibility and progression.
12
Should we invest in this program?
PRIMESuspect™ to predict the probability of a drug program's approval, for a specific target-indication pair.